Collegium Pharmaceutical, Inc. (COLL) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call summary and Q&A indicate a positive sentiment. The company reported strong financial performance, with revenue and EBITDA growth, and raised 2025 guidance. Despite increased operational costs, the strategic focus on Jornay PM and share repurchases is promising. The Q&A highlighted stable demand and no significant competitive threats. However, some management responses were vague, slightly tempering enthusiasm. With a market cap of $1.06 billion, the stock is likely to see a positive reaction, between 2% to 8%, given the strong growth and strategic initiatives.
Key Financial Performance
Full Year Net Revenues $780.6 million, up 24% year-over-year. This growth was attributed to strong commercial execution and strategic investments.
Adjusted EBITDA $460.5 million, up 15% year-over-year. The increase was driven by robust financial performance across the portfolio.
Jornay PM Net Revenue $148.9 million, up 48% year-over-year compared to pro forma 2024 revenue. Growth was due to increased prescriptions (up 20% year-over-year) and sales and marketing investments.
Pain Portfolio Revenue $631.7 million, up 6% year-over-year. Growth was supported by all three core pain medicines delivering full-year growth.
Cash from Operations $329.3 million, up significantly from the prior year. This increase was driven by strong revenue performance and operational efficiency.
Cash Balance $386.7 million, up approximately $224 million from the end of 2024. This was due to strong cash flow generation and disciplined financial management.
Belbuca Net Revenue $221.7 million, up 5% year-over-year. Growth was attributed to strong brand fundamentals and a growing prescriber base.
Xtampza ER Net Revenue $199.3 million, up 4% year-over-year. Growth was supported by its differentiation and favorability in the market.
Nucynta Franchise Net Revenue $196.3 million, up 11% year-over-year. Growth was primarily due to profitability improvements from managing gross-to-nets.
GAAP Net Income $62.9 million, down 9% year-over-year. The decline was impacted by a one-time loss on extinguishment of debt related to refinancing.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Jornay PM growth: Jornay PM prescriptions grew by 20% year-over-year, generating $148.9 million in net revenue, up 48% compared to pro forma 2024 revenue. Prescriptions reached over 760,000 in 2025, with a 16% year-over-year increase in Q4. The product is expected to generate $190-$200 million in 2026, representing over 30% annual growth.
Market share and prescriber growth: Jornay PM's market share in the long-acting branded methylphenidate market grew to nearly 26% in Q4, up 6.5 percentage points year-over-year. The prescriber base reached an all-time high of over 29,000 in Q4, up 21% year-over-year.
Pain portfolio performance: The pain portfolio generated $631.7 million in 2025, up 6% year-over-year. Belbuca, Xtampza ER, and the Nucynta franchise all delivered full-year growth. The portfolio represents approximately half of the branded ER market.
Financial performance: Full-year 2025 net revenues were $780.6 million, up 24% year-over-year, and adjusted EBITDA was $460.5 million, up 15% year-over-year. Operating cash flows were $329.3 million, and the company ended the year with $386.7 million in cash.
Capital deployment strategy: The company closed a $980 million syndicated credit facility, improving interest rates and debt terms. It repurchased $25 million in shares and has $150 million remaining in its repurchase program. The strategy focuses on portfolio expansion, debt repayment, and share repurchases.
Authorized generics agreement: In January, Collegium announced supply and quality agreements with Hikma Pharmaceuticals for authorized generics of Nucynta and Nucynta ER, providing significant profit share and competitive positioning against third-party generics.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Market Competition: The company faces competitive pressures in the ADHD and pain management markets, with the need to differentiate its products like Jornay PM and its pain portfolio to maintain and grow market share.
Regulatory and Generic Competition: The launch of authorized generics for Nucynta and Nucynta ER by Hikma Pharmaceuticals could impact revenue streams, despite profit-sharing agreements.
Economic and Seasonal Dynamics: Annual deductible resets and higher out-of-pocket costs for patients in Q1 create seasonal revenue pressures, which could affect financial performance.
Operational Costs: Increased operating expenses due to commercialization efforts for Jornay PM and targeted investments in sales and marketing could strain profitability.
Debt and Financial Flexibility: While the new syndicated credit facility improves terms, the company still carries significant debt, which could limit financial flexibility in adverse conditions.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Jornay PM Revenue Growth: The company expects Jornay PM revenue to be in the range of $190 million to $200 million in 2026, representing a 31% increase year-over-year. This growth is attributed to the full-year benefit of expanded sales force and marketing campaigns initiated in 2025.
Pain Portfolio Durability: The company anticipates continued durability and robust cash flows from its pain portfolio, which includes Belbuca, Xtampza ER, and the Nucynta franchise. These revenues are expected to remain stable and provide a strong financial foundation for future investments.
Total Product Revenue: Collegium projects total product revenues in the range of $805 million to $825 million for 2026, a 4% increase year-over-year. This includes the impact of the authorized generic agreement with Hikma for the Nucynta franchise.
Adjusted EBITDA: The company expects adjusted EBITDA in the range of $455 million to $475 million in 2026, reflecting a 1% year-over-year increase.
Authorized Generic Agreement Impact: The authorized generic agreement with Hikma for Nucynta and Nucynta ER is expected to provide significant profit share and allow Collegium to compete effectively with third-party generics.
Capital Deployment Strategy: Collegium plans to continue disciplined capital deployment, balancing portfolio expansion through business development, debt repayment, and opportunistic share repurchases. The new $980 million syndicated credit facility provides additional flexibility for these initiatives.
Market Expansion for Jornay PM: The company aims to further penetrate the adult ADHD market and increase awareness among healthcare providers and patients. New marketing campaigns and expanded sales force efforts are expected to drive additional growth.
Gross-to-Net Stability for Jornay PM: Gross-to-net ratios for Jornay PM are expected to remain stable in the mid-60% range throughout 2026, with seasonal fluctuations anticipated.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Share Repurchase Program: In 2025, Collegium repurchased $25 million in shares through its share repurchase program. This was highlighted as an important component of their capital deployment strategy. Additionally, the company has $150 million remaining in its current Board-authorized repurchase program, which can be leveraged through December 31, 2026.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What assumptions underlie 2026 Jornay guidance?
A:The growth is expected to be driven by demand growth with relative stability in gross to net between 2025 and 2026.
Q:Have there been any competitive developments in the ADHD market that could impact Jornay demand?
A:No significant changes have been observed in current dynamics or future launches that could impact Jornay demand. Jornay remains differentiated due to its proprietary delivery technology.
Q:Can you provide a peak sales range for Jornay and the expected ramp to peak?
A:The company has not provided a peak sales range for Jornay. They are currently investing in sales and marketing, with an expanded sales team showing impact. They will provide updates once they have a better sense of the commercial investments' impact.
Q:How promotionally sensitive are Belbuca and Xtampza at this stage of their life cycle?
A:Belbuca and Xtampza are highly promotionally sensitive due to the complex marketplace. The sales team helps offices navigate the payer environment and change behavior. The company has 100 sales representatives supporting $600 million+ revenue.
Q:How does the company plan to handle potential generic competition for Belbuca and Xtampza?
A:The company will invest through potential LOE dates due to uncertainty. If an event occurs, they can quickly pivot and moderate investment.
Q:What is the company's approach to capital deployment, particularly regarding rare diseases?
A:The company is open to acquiring commercial or near-commercial U.S.-based assets with LOEs into the 2030s and beyond. They prefer assets in psychiatry and pediatrics but are also open to rare diseases due to their capital efficiency and potential for building a franchise with patient services and reimbursement hubs.
Q:What is the company's stance on expanding the Jornay sales force?
A:The company believes the current sales force of 180 reps is the right size based on prescriber behavior and deciles. They may revisit expansion if needed in the future.
Q:Review of Unclear Management Responses
A:The company avoided providing a peak sales range for Jornay, stating they are still assessing the impact of commercial investments. Additionally, while discussing capital deployment, the response was broad and lacked specific details about potential acquisitions or timelines.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Full Conference
Nucynta franchise
agreement share
benefit sale
care provider
closing credit
creation progress
credit facility
deployment capital
depth prescribing
draw term
dynamic pressure
effort marketing
evidence
expansion diversification
facility interest
generic
health care
marketing campaign
marketing investment
net
payer
pediatrics
pocket patient
reset pocket
revenue pain
sale marketing
school season
segment
term loan
term value
value creation
COLL Transcript
Collegium Pharmaceutical, Inc. (COLL) Q1 2026 Earnings Call Transcript
Positive5-7
The earnings call highlights strong financial performance with a 15% revenue increase and improved gross margins. The strategic outlook is optimistic, focusing on future-oriented initiatives. Despite acknowledging risks, the growth in net income and cash flow supports a positive sentiment. Given the small market cap, the stock is likely to react positively within the 2% to 8% range.
Collegium Pharmaceutical, Inc. (COLL) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
Neutral3-11
Collegium Pharmaceutical, Inc. (COLL) Q4 2025 Earnings Call Transcript
Positive2-26
The earnings call summary and Q&A indicate a positive sentiment. The company reported strong financial performance, with revenue and EBITDA growth, and raised 2025 guidance. Despite increased operational costs, the strategic focus on Jornay PM and share repurchases is promising. The Q&A highlighted stable demand and no significant competitive threats. However, some management responses were vague, slightly tempering enthusiasm. With a market cap of $1.06 billion, the stock is likely to see a positive reaction, between 2% to 8%, given the strong growth and strategic initiatives.
Collegium Pharmaceutical, Inc. (COLL) Q3 2025 Earnings Call Transcript
Positive11-6
The company reported record high revenue and strong earnings, coupled with optimistic guidance and a raised financial outlook. Despite some uncertainties in strategic execution and M&A specifics, the market is likely to react positively due to robust financial performance, a significant share repurchase program, and strategic growth initiatives. Given the company's small-cap status, these factors are expected to drive a positive stock price movement in the short term.
COLL Slides
COLL Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
